Duration of Anti-PD-1 Therapy in Metastatic Melanoma

NCT02821013 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

614

Enrollment

NETWORK

Sponsor class

Conditions

Unresectable/Metastatic Melanoma

Interventions

DRUG: Intermittent PD-1 inhibitor therapy
DRUG: Continuous PD-1 inhibitor therapy

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]